Breast cancer patients struggle with several unmet emotional and financial concerns

Although breast cancer is the most common non-skin cancer diagnosed in women, finding support during treatment and through survivorship can be incredibly challenging.

Runimotamab by Genentech USA for Solid Tumor: Likelihood of Approval

Share this article GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug

December 22, 2023

Oncolytic Virus for Human Papillomavirus Associated Cancer, Human Papillomavirus Infections and Coronavirus Disease 2019 (COVID-19) by Blue Sky Immunotherapies for Cervical Cancer: Likelihood of Approval

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes

October 26, 2023

Curie.Bio has a new $340M fund; Layoffs at Benchling, I-Mab

Plus, news about Cullinan Therapeutics, Regulus and Imvax: Curie.Bio’s new $340M fund: The investment firm and biotech startup incubator disclosed the … Sign up to

January 30, 2025

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.